RT Journal Article
SR Electronic
T1 Pharmacological Management of Acute Spinal Cord Injury: A longitudinal multi-cohort observational study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.28.21257947
DO 10.1101/2021.05.28.21257947
A1 Jutzeler, Catherine R.
A1 Bourguignon, Lucie
A1 Tong, Bobo
A1 Ronca, Elias
A1 Bailey, Eric
A1 Harel, Noam Y.
A1 Geisler, Fred
A1 Ferguson, Adam R.
A1 Kwon, Brian K.
A1 Cragg, Jacquelyn J.
A1 Grassner, Lukas
A1 Kramer, John L.K.
YR 2021
UL http://medrxiv.org/content/early/2021/05/31/2021.05.28.21257947.abstract
AB Background Nearly every individual sustaining traumatic spinal cord injury receives multiple types and classes of medications to manage a litany of secondary complications. Prior clinical studies and evidence from animal models suggest that several of these medications could enhance or impede endogenous neurological recovery. However, there is a knowledge gap surrounding the spectrum of pharmacologic agents typically administered in the routine management of spinal cord injury.Objective To systematically determine the types of medications commonly administered, alone or in combination, in the acute to subacute phase of spinal cord injury.Methods We conducted an analysis of two largescale cohorts (the Sygen interventional trial and the SCIRehab observational cohort study) to determine what constitutes “ standards of acute pharmacological care” after spinal cord injury. Concomitant medication use, including dosage, timing and reason for administration, was tracked. Descriptive statistics were used to describe the medications administered within the first 60 days after spinal cord injury.Results Across 2040 individuals with spinal cord injury, 775 unique medications were administered within the two months after injury. On average, patients enrolled in the Sygen trial received 9.9 ± 4.9 (range 0-34), 14.3 ± 6.3 (range 1-40), 18.6 ± 8.2 (range 0-58), and 21.5 ± 9.7 (range 0-59) medications within the first 7, 14, 30, and 60 days post-injury, respectively. Patients enrolled in the SCIRehab cohort study received on average 1.7 ± 1.7 (range 0-11), 3.7 ± 3.7 (range 0-24), 8.5 ± 6.3 (range 0-42), and 13.5 ± 8.3 (range 0-52) medications within the first 7, 14, 30, and 60 days post-injury, respectively. Polypharmacy was commonplace (up to 43 medications per day per patient). Approximately 10% of medications were administered acutely as prophylaxis (e.g., against the development of pain or infections).Conclusions To our knowledge, this was the first time acute pharmacological practices have been comprehensively examined after spinal cord injury. Our study revealed a high degree of polypharmacy in the acute stages of spinal cord injury, with potential to both positively and negatively impact neurological recovery. This data may provide key insight to achieve better understanding of how the acute pharmacological management of spinal cord injury affects long-term recovery. All results can be interactively explored on the RXSCI web site (https://jutzelec.shinyapps.io/RxSCI/) and GitHub repository (https://github.com/jutzca/Acute-Pharmacological-Treatment-in-SCI/).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by research grants from the Swiss National Science Foundation (Ambizione Grant #PZ00P3_186101, Jutzeler), Wings for Life Research Foundation (#2017_044, Jutzeler and Kramer), and Craig H. Nielsen Foundation (Cragg and Jutzeler).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval for this study (secondary analysis) was received by an institutional ethical standards committee on human experimentation at the University of British Columbia. The original Sygen clinical trial (results published elsewhere) also received ethical approval, but was conducted before clinical trials were required to be registered (i.e., no clinicaltrial.gov identifier available). Each participating center of the SCIRehab study received institutional review board approval for this study and obtained informed consent from each patient (or their parent/guardian).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFull anonymized data of both data sources will be shared at the request from any qualified investigator (please contact the Corresponding Author). The code for the data analysis and visualization is available in our GitHub repository (https://github.com/jutzca/Acute-Pharmacological-Treatment-in-SCI/).